

Why carry out this study?

- An unmet need exists for drug treatments that address the causes of dry eye, such as oxidative stress
- The study assessed whether mitochondria-targeted SkQ1 treatment reduced the signs and symptoms of dry eye disease compared to placebo

What was learned from the study?

- SkQ1 treatment was effective and safe for treating dry eye signs and symptoms
- Mitochondrial-targeted antioxidants such as SkQ1 provide a novel approach to dry eye treatment

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Mitotech S.A. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).